Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Zhejiang Haisen Pharmaceutical Co. Ltd. A ¥16.73, price ¥21.50, upside -22.2%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Zhejiang Haisen Pharmaceutical Co. Ltd. A for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
41‑month range ¥12.97 – ¥36.33 · fair‑value band ¥11.32 – ¥21.74 · the ¥21.50 price screens above the ¥16.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Zhejiang Haisen Pharmaceutical Co. Ltd. A in your weekly email
Every Wednesday you see whether Zhejiang Haisen Pharmaceutical Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally.
Show more
Zhejiang Haisen Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients, and preparations in China and internationally. The company offers active pharmaceutical ingredients for use as antilipemic agents, antipyretic analgesics, antidepressants, analgesics, antibacterial agents, histamine drugs, and anticonvulsants, as well as for anti-gastric ulcers, and digestive and cardiovascular applications. It also provides chemical products for use as paroxetine HCl and amikacin sulphate intermediates and food additives; and escitalopram oxalate tablets to treat depression and panic disorders under the Tezi brand. In addition, the company engages in the import and export of goods; trading; and medical research and experimental development activities. Zhejiang Haisen Pharmaceutical Co., Ltd. was incorporated in 1998 and is headquartered in Dongyang, China.
Stock analysis
Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) currently trades at ¥21.50, while our model-based Fair Value estimate is ¥16.73, implying the stock looks roughly 28.5% overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥16.73 per share, and 4 of the 26 models we run sit above the ¥21.50 price.
Bear case: the Asset-Based group reads lowest at ¥6.57, and 22 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: ¥11.32 (bear) to ¥21.74 (bull), the price of ¥21.50 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Zhejiang Haisen Pharmaceutical Co. Ltd. A reported revenue of 532M CNY in FY2025 versus 389M CNY in FY2021, a compound +8.2%/yr. Reported net income was 136M CNY in FY2025, compounding +9.6%/yr from FY2021.
Key figures
Market cap 3.3B CNY (≈ $489M) · P/E ratio 24.4 · P/S ratio 6.24 · EPS (TTM) ¥0.8800 · Dividend yield 0.5% · Net margin 25.5% · Return on equity 9.2% · Return on assets (EBIT) 13.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (medium confidence).
What moves the price
The share trades about 21% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at −22%, 001367 screens richer than that median.
Fair Value models
Bear ¥11.32Fair Value ¥16.73Bull ¥21.74
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.5610 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.0%
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+1.2%
Dividend (yield on the price)0.5%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.28% → 28%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+42.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +39.7% a year for the price.
Compare Zhejiang Haisen Pharmaceutical Co. Ltd. A with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−22% · Below median
Profitability
Return on equity (TTM)9% · Below median
Return on assets6% · Below median
Net margin (TTM)26% · Top 25%
Operating margin (TTM)30% · Above median
Growth and dividend
Revenue growth−10% · Bottom 25%
Dividend yield (TTM)0.5% · Bottom 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Zhejiang Haisen Pharmaceutical Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/001367
Frequently asked questions
Is Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥16.73 versus a price of ¥21.50, about −22% upside (overvalued).
What is the fair value of 001367?
Our model-based fair value for Zhejiang Haisen Pharmaceutical Co. Ltd. A is ¥16.73 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥21.50.
What is the quality score of 001367?
Zhejiang Haisen Pharmaceutical Co. Ltd. A has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Our model-based price target is the fair value of ¥16.73 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario ¥11.32, optimistic scenario ¥21.74. It is a calculation from audited fundamentals, not an analyst target.
What is the Zhejiang Haisen Pharmaceutical Co. Ltd. A stock forecast for 2026?
Our models put fair value at ¥16.73, about −22% upside versus a price of ¥21.50 (overvalued). Cautious scenario ¥11.32, optimistic scenario ¥21.74. The calculation is refreshed regularly with new filings.
What is the revenue of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Zhejiang Haisen Pharmaceutical Co. Ltd. A reported trailing-twelve-month revenue of about 521M CNY (latest available figure, as of Sep 24, 2026).
Does Zhejiang Haisen Pharmaceutical Co. Ltd. A pay a dividend?
Zhejiang Haisen Pharmaceutical Co. Ltd. A currently shows a dividend yield of about 0.54% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
For today's price to be fair in a discounted-cash-flow model, Zhejiang Haisen Pharmaceutical Co. Ltd. A would have to grow free cash flow by +42.1 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +8.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 001367 use?
Our models discount Zhejiang Haisen Pharmaceutical Co. Ltd. A at 10.4 %: a base by market capitalisation (small), damped by beta 0.13, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Zhejiang Haisen Pharmaceutical Co. Ltd. A that is +42.1 % per year a year over ten years, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) delivered so far?
Over the past 4 years revenue at Zhejiang Haisen Pharmaceutical Co. Ltd. A grew +8.2 % a year. The price currently implies +42.1 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Zhejiang Haisen Pharmaceutical Co. Ltd. A (+42.1 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The free-cash-flow yield on the price is 0.77 %: that much free cash flow Zhejiang Haisen Pharmaceutical Co. Ltd. A produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zhejiang Haisen Pharmaceutical Co. Ltd. A it is ¥16.73 per share (as of Sep 24, 2026), against a price of ¥21.50. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Zhejiang Haisen Pharmaceutical Co. Ltd. A stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 001367 trades above its calculated fair value: price ¥21.50, fair value ¥16.73, a gap of about −22% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 001367?
No. The price is what the market pays today (¥21.50); the fair value is what the company's own numbers justify (¥16.73). For Zhejiang Haisen Pharmaceutical Co. Ltd. A the two are ¥4.77 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zhejiang Haisen Pharmaceutical Co. Ltd. A worth?
The market values Zhejiang Haisen Pharmaceutical Co. Ltd. A at about 3.3B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥21.50; our models calculate a fair value of ¥16.73 per share.
What do the bullish and bearish scenarios say about 001367?
Our models span a range for Zhejiang Haisen Pharmaceutical Co. Ltd. A: cautious scenario ¥11.32, base ¥16.73, optimistic ¥21.74 per share (as of Sep 24, 2026, price ¥21.50). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 001367?
Zhejiang Haisen Pharmaceutical Co. Ltd. A trades at a price-to-earnings ratio of 24.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥16.73 is built from several models across several years. Other multiples: P/B 2.2, P/S 6.3, EV/EBITDA 14.3.
How solid is the balance sheet of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Balance-sheet figures for Zhejiang Haisen Pharmaceutical Co. Ltd. A (as of Sep 24, 2026): return on equity 9.2%. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is 001367 from its 52-week high?
Zhejiang Haisen Pharmaceutical Co. Ltd. A trades at ¥21.50, about 21% below its 52-week high of ¥27.27 and 27% above the low of ¥16.96 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of ¥16.73 is for.
Which stocks are comparable to Zhejiang Haisen Pharmaceutical Co. Ltd. A?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zhejiang Haisen Pharmaceutical Co. Ltd. A stock attractive at the current price?
The data as of Sep 24, 2026: price ¥21.50, calculated fair value ¥16.73 (−22%), Quality Score 52/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 001367 calculated?
We run Zhejiang Haisen Pharmaceutical Co. Ltd. A through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥16.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Zhejiang Haisen Pharmaceutical Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The closing price on Sep 24, 2026 was ¥21.50. Our model-based fair value is ¥16.73, about −22% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zhejiang Haisen Pharmaceutical Co. Ltd. A right now?
Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥11.32 to ¥21.74) leaves room in how you read the outcome.
Key figures of Zhejiang Haisen Pharmaceutical Co. Ltd. A
How large is the market capitalisation of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The market capitalisation of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 3.3B CNY (≈ $489M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The price-to-sales ratio of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 6.24 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Earnings per share at Zhejiang Haisen Pharmaceutical Co. Ltd. A are ¥0.8800 (price ÷ EPS = P/E 24.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The dividend yield of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 0.5% (payout 13.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The net margin of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 25.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The return on equity (ROE) of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 9.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
On an EBIT basis the return on assets of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 13.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
The operating margin of Zhejiang Haisen Pharmaceutical Co. Ltd. A is 30.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Revenue at Zhejiang Haisen Pharmaceutical Co. Ltd. A is growing −9.5% versus a year earlier (3y avg +8.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zhejiang Haisen Pharmaceutical Co. Ltd. A (001367)?
Earnings per share at Zhejiang Haisen Pharmaceutical Co. Ltd. A are growing −5.0% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Zhejiang Haisen Pharmaceutical Co. Ltd. A in the live analysis
One click puts Zhejiang Haisen Pharmaceutical Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
